About The Study: This nonrandomized controlled trial of 108 patients with advanced Parkinson disease found that at 5-year follow-up quality of life remained stable in the deep brain stimulation of the subthalamic nucleus (STN-DBS) group and worsened in the standard-of-care medication group, mainly driven by the favorable effect of STN-DBS on mobility. These findings may provide helpful information when counseling patients on the efficacy of STN-DBS for Parkinson disease and monitoring patients postoperatively in long-term follow-up.
Authors: Stefanie T. Jost, Ph.D., and Haidar S. Dafsari, M.D., of the University of Cologne, Germany, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.52177)
